🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 30/04/2019 | 173,93 | 174,92 | 168,49 | 168,98 | -2,05% | 3,70% | 1.619.800 |
| 29/04/2019 | 172,58 | 173,67 | 171,22 | 172,52 | -0,19% | 1,42% | 750.300 |
| 26/04/2019 | 173,98 | 174,42 | 170,01 | 172,85 | -1,01% | 2,53% | 1.117.700 |
| 25/04/2019 | 172,40 | 175,22 | 170,20 | 174,61 | +1,18% | 2,91% | 806.500 |
| 24/04/2019 | 175,58 | 175,86 | 171,76 | 172,58 | -1,59% | 2,34% | 1.164.500 |
| 23/04/2019 | 169,22 | 175,60 | 168,77 | 175,37 | +4,06% | 4,04% | 1.514.600 |
| 22/04/2019 | 167,79 | 169,86 | 166,20 | 168,52 | +0,21% | 2,18% | 1.213.500 |
| 18/04/2019 | 169,96 | 170,45 | 163,68 | 168,16 | +0,71% | 3,98% | 3.195.700 |
| 17/04/2019 | 180,45 | 180,75 | 166,65 | 166,97 | -7,10% | 7,81% | 2.851.100 |
| 16/04/2019 | 183,63 | 184,80 | 179,59 | 179,74 | -1,51% | 2,84% | 900.300 |
| 15/04/2019 | 182,27 | 184,32 | 180,24 | 182,49 | -0,16% | 2,24% | 826.700 |
| 12/04/2019 | 185,42 | 186,47 | 182,31 | 182,78 | -1,26% | 2,24% | 1.077.400 |
| 11/04/2019 | 191,08 | 191,42 | 184,22 | 185,12 | -2,76% | 3,77% | 1.971.900 |
| 10/04/2019 | 188,32 | 191,71 | 187,07 | 190,37 | +1,09% | 2,46% | 1.155.900 |
| 09/04/2019 | 188,01 | 189,70 | 187,75 | 188,31 | -0,33% | 1,04% | 976.000 |
| 08/04/2019 | 189,27 | 189,95 | 186,67 | 188,93 | +0,02% | 1,73% | 910.100 |
| 05/04/2019 | 184,49 | 189,35 | 184,24 | 188,89 | +2,57% | 2,77% | 2.289.000 |
| 04/04/2019 | 188,22 | 188,34 | 182,49 | 184,15 | -1,99% | 3,11% | 1.193.400 |
| 03/04/2019 | 187,90 | 188,98 | 187,01 | 187,89 | +0,42% | 1,05% | 829.400 |
| 02/04/2019 | 185,96 | 189,43 | 184,91 | 187,11 | +0,57% | 2,43% | 814.400 |
| 01/04/2019 | 185,20 | 187,38 | 184,68 | 186,05 | +1,14% | 1,46% | 1.030.000 |
| 29/03/2019 | 184,29 | 184,86 | 181,92 | 183,95 | +0,84% | 1,60% | 1.274.700 |
| 28/03/2019 | 186,01 | 186,94 | 181,49 | 182,42 | -1,83% | 2,93% | 1.615.200 |
| 27/03/2019 | 190,00 | 190,01 | 185,62 | 185,82 | -2,15% | 2,31% | 1.181.200 |
| 26/03/2019 | 185,24 | 190,07 | 184,83 | 189,91 | +3,30% | 2,83% | 1.373.700 |
| 25/03/2019 | 181,67 | 185,06 | 181,44 | 183,85 | +1,28% | 1,99% | 1.754.500 |
| 22/03/2019 | 182,07 | 183,85 | 181,04 | 181,53 | -0,56% | 1,54% | 1.612.300 |
| 21/03/2019 | 178,22 | 182,74 | 178,22 | 182,56 | +1,43% | 2,54% | 1.156.500 |
| 20/03/2019 | 181,53 | 182,46 | 179,54 | 179,98 | -0,98% | 1,61% | 1.213.600 |
| 19/03/2019 | 184,64 | 185,00 | 181,18 | 181,76 | -3,05% | 2,07% | 1.556.200 |